Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Greggs warns FY25 operating profits could be 'modestly below' FY24

(Sharecast News) - Bakery chain Greggs warned on Wednesday that FY25 operating profits may be "modestly below" FY24 despite H1 sales growth. Greggs saw total H1 sales grow 6.9% to £1.02bn, with like-for-like sales up 2.6% year-on-year.

Greggs said it had made "good progress" in May but noted this was followed by "slower growth" in June as high temperatures affected the UK, increasing demand for cold drinks but reducing overall footfall.

The FTSE 250-listed firm said it had opened 87 new shops and closed 56 shops in H1, leaving a total of 2,649 shops trading as at 28 June and stated it was confident in achieving 140 to 150 net openings for FY25.

Looking forward, Greggs expects H1 operating profits to be lower year-on-year, due to both its strong comparative trading performance in H124 and the phasing of refurbishments and cost recovery initiatives in FY25.

However, as it acknowledged that comparative like-for-like sales were generally "less demanding" in H2, Greggs said it now anticipates that the FY operating profits "could be modestly below that achieved in 2024".

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.